PharmaSurgics patented drug candidate PXL01, has demonstrated an excellent effect and safety profile in preclinical studies and the first clinical trial on patients are planned to start in
The FlexStent femoropopliteal self expanding stent system is indicated for the treatment of peripheral vascular lesions involving the superficial femoral and popliteal arteries. The fully connected flexible FlexStent
The new kits are optimized for characterization of proteins in the MEK and ERK families, which play critical roles in cancer cell survival and proliferation. Drug developers have
Highmark and Independence Blue Cross (IBC) have submitted the applications to the Pennsylvania Insurance Department (PID) in April 2007. In a joint statement, Kenneth Melani, president and CEO
The site has a new purpose-built, 100-bed facility designed to run clinical pharmacology studies in healthy, diabetic and obese participants. Well-known for conducting first-in-human, proof-of-concept studies and participating
Further, Corbett and ltf Labortechnik filed an intervention in opposition proceedings before the European Patent Office. QIAGEN acquired Corbett, an Australian instrumentation manufacturing company, in July 2008. In
Pursuant to the terms of the agreement, Medline will serve as the group’s primary distributor providing medical and surgical products and services. The agreement will focus on driving
Ecard is a tablet taken orally once daily and the two approved formulations are ‘Ecard LD’ and ‘Ecard HD’; 4mg candesartan cilexetil/6.25mg hydrochlorothiazide and 8mg candesartan cilexetil/6.25mg hydrochlorothiazide,
Recalbon tablets 1mg or Bonoteo tablets 1mg (Minodronic acid hydrate) is an orally taken bisphosphonate that was first discovered in Japan and reportedly exhibits extremely potent inhibition of
The proposed transaction reflects Biovitrum’s previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics. Biovitrum has engaged Nomura Code in this process. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.